Benefit-Risk SIG

The Benefit-Risk SIG was set up at the start of 2012 to help support those involved in this fast evolving area.

The main aims of the SIG are:

• To understand how best to apply Benefit-Risk Methodologies across the Pharmaceutical Industry
• To discuss and make recommendations on key methodological issues
• To share examples of how Benefit-Risk has been used within pharmaceutical companies
• To share external information including new developments around Benefit-Risk

Currently the SIG has subgroups working on:
 
• Literature review
• Points to consider for creating effects tables
• MCDA/SMAA
• Benefit-Risk in the HTA setting (together with the HTA SIG)
• Training
• Bayesian applications in Benefit-Risk
• Benefit-Risk BLOG

If you have an interest in being involved in this SIG or have an interesting case study or experience of carrying out a structured Benefit-Risk assessment to share, please contact Alexander Schacht

email: Schacht_alexander@lilly.com

Our BLOG can be found under www.benefit-risk-assessment.com

Latest News


Show all news

EventsFuture Events


  • Patient Engagement in Clinical Trials Webinar - Dates: 13 – 13 Jun, 2017

    Following on from the successful and thought-provoking presentation at last year’s PSI conference by Paul Wicks from PatientsLikeMe, this webinar will continue to explore the ways in which patients are influencing the design of new clinical trials.
  • BBS / PSI One-day Event on Cancer Immunotherapy - Dates: 15 Jun, 2017

    This joint Basel Biometric Society / PSI one day meeting will present an overview of the science and potential statistical challenges across a range of topics covering early and late phases of development, regulatory and health technology assessments.
Merck Logo2

Associate Director, Biostatistician

read more...

Leeds-80x250

Medical Statistician / Senior Medical Statistician

read more...

Astrazeneca

Associate Director, Statistics Team leader - Early Clinical Development

read more...

Astrazeneca

Early Clinical Development – various levels

read more...

LOGO

Biostatistics Head of Department

read more...

Astrazeneca

Principal Statistician – Centralised Statistical Monitoring

read more...

Astrazeneca

Clinical Trial Design Methodology Expert - Statistical Innovation Team

read more...